Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery

Molecular Neurobiology

Volumn 51, Issue 1, 2015, Pages 1-7

  Liu, Yu Hui ^a   Wang, Ye Ran ^a   Xiang, Yang ^a   Zhou, Hua Dong ^a   Giunta, Brian ^b   Mañucat Tan, Noralyn B ^c   Tan, Jun ^b   Zhou, Xin Fu ^c   Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Adverse effects; Alzheimer s disease; Amyloid beta; Immunotherapy; Peripheral clearance

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BIOLOGICAL MODEL; BLOOD; BRAIN; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL;

EID: 84939891140     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8694-9     Document Type: Review

References (60)

1. Dodel R et al (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233–243. doi:10.1016/S1474-4422(13)70014-0
2. Doody RS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321. doi:10.1056/NEJMoa1312889
3. Karran E, Hardy J (2014) Antiamyloid therapy for Alzheimer’s disease—are we on the right road? N Engl J Med 370:377–378. doi:10.1056/NEJMe1313943
4. Salloway S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370:322–333. doi:10.1056/NEJMoa1304839
5. Wang YJ (2014) Lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10:188–189. doi:10.1038/nrneurol.2014.44
6. Wang YJ, Zhou HD, Zhou XF (2010) Modified immunotherapies against Alzheimer’s disease: toward safer and effective amyloid clearance. J Alzheimer Dis 21:1065–1075
7. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 98:8850–8855
8. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM (2002) Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science 295:2264–2267
9. Morgan D (2011) Immunotherapy for Alzheimer’s disease. J Int Med 269:54–63. doi:10.1111/j.1365-2796.2010.02315.x
10. Sperling R et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241–249. doi:10.1016/S1474-4422(12)70015-7
11. Carlson C et al (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer’s disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimer Dement 7:396–401. doi:10.1016/j.jalz.2011.05.2353
12. Gilman S et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562
13. Millucci L, Ghezzi L, Bernardini G, Santucci A (2010) Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Peptide Sci 11:54–67
14. Colletier JP et al (2011) Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A 108:16938–16943. doi:10.1073/pnas.1112600108
15. Mannix RC, Whalen MJ (2012) Traumatic brain injury, microglia, and Beta amyloid. Int J Alzheimer Dis 2012:608732. doi:10.1155/2012/608732
16. Dilger RN, Johnson RW (2008) Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J Leukoc Biol 84:932–939. doi:10.1189/jlb.0208108
17. Pietri M et al (2013) PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer’s diseases. Nat Med 19:1124–1131. doi:10.1038/nm.3302
18. Krstic D, Knuesel I (2012) Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 9:25–34. doi:10.1038/nrneurol.2012.236
19. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A (2013) Integrative genomics identifies APOE epsilon4 effectors in Alzheimer’s disease. Nature 500:45–50. doi:10.1038/nature12415
20. Ohtani S, Kohyama K, Matsumoto Y (2011) Autoantibodies recognizing native MOG are closely associated with active demyelination but not with neuroinflammation in chronic EAE. Neuropathology 31:101–111. doi:10.1111/j.1440-1789.2010.01131.x
21. Patton RL et al (2006) Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer’s disease patients: a biochemical analysis. Am J Pathol 169:1048–63
22. Deng J et al (2012) Autoreactive-Abeta antibodies promote APP beta-secretase processing. J Neurochem 120:732–740. doi:10.1111/j.1471-4159.2011.07629.x
23. Dodel R et al (2011) Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease. J Neurosci 31:5847–5854. doi:10.1523/JNEUROSCI.4401-10.2011
24. Piazza F et al (2013) Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol 73:449–458. doi:10.1002/ana.23857
25. Bouras C, Riederer BM, Hof PR, Giannakopoulos P (2003) Induction of MC-1 immunoreactivity in axons after injection of the Fc fragment of human immunoglobulins in macaque monkeys. Acta Neuropathol 105:58–64. doi:10.1007/s00401-002-0617-6
26. Farlow M et al (2012) Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 8:261–271. doi:10.1016/j.jalz.2011.09.224
27. Bradshaw EM et al (2013) CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16:848–850. doi:10.1038/nn.3435
28. Bard F et al (2012) Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol 238:38–43. doi:10.1016/j.expneurol.2012.07.022
29. Wang YJ et al (2010) Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer’s disease. Brain Behav Immun 24:1281–1293. doi:10.1016/j.bbi.2010.05.010
30. Wang YJ et al (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer’s disease. Neurobiol Aging 30:364–376. doi:10.1016/j.neurobiolaging.2007.06.013
31. Fukumoto H, Deng A, Irizarry MC, Fitzgerald ML, Rebeck GW (2002) Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. J Biol Chem 277:48508–48513. doi:10.1074/jbc.M209085200
32. Hooijmans CR, Kiliaan AJ (2008) Fatty acids, lipid metabolism and Alzheimer pathology. Eur J Pharmacol 585:176–196. doi:10.1016/j.ejphar.2007.11.081
33. Lesser GT (2012) Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. Neurology 78:1280. doi:10.1212/WNL.0b013e318254f6ad
34. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240:622–630
35. Zerbinatti CV, Bu G (2005) LRP and Alzheimer’s disease. Rev Neurosci 16:123–135
36. Kang DE et al (2000) Modulation of amyloid beta-protein clearance and Alzheimer’s disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106:1159–1166. doi:10.1172/JCI11013
37. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35:2628–2631
38. Koldamova R, Staufenbiel M, Lefterov I (2005) Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280:43224–43235. doi:10.1074/jbc.M504513200
39. Koldamova RP et al (2003) 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem 278:13244–13256. doi:10.1074/jbc.M300044200
40. Liu Y et al (2009) Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 17:1381–1386. doi:10.1038/mt.2009.115
41. Torkhovskaia TI, Ipatova OM, Medvedeva NV, Zakharova TS, Khalilov EM (2006) Membrane proteins and phospholipids as effectors of reverse cholesterol transport. Biomed Khim 52:113–123
42. Zarubica A, Trompier D, Chimini G (2007) ABCA1, from pathology to membrane function. Pflugers Arch 453:569–579. doi:10.1007/s00424-006-0108-z
43. Sparks DL (2007) Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Abeta through the liver. Curr Alzheimer Res 4:165–169
44. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72:850–855. doi:10.1124/mol.107.036913
45. Seliger SL et al (2004) Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol 15:1904–1911
46. Li J et al (2011) Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76:1485–1491. doi:10.1212/WNL.0b013e318217e7a4
47. Li J et al (2010) Vascular risk aggravates the progression of Alzheimer’s disease in a Chinese cohort. J Alzheimers Dis 20:491–500. doi:10.3233/JAD-2010-1383
48. Arvanitakis Z, Lucas JA, Younkin LH, Younkin SG, Graff-Radford NR (2002) Serum creatinine levels correlate with plasma amyloid Beta protein. Alzheimer Dis Assoc Disord 16:187–190
49. Stanyon HF, Viles JH (2012) Human serum albumin can regulate amyloid-beta peptide fiber growth in the brain interstitium: implications for Alzheimer disease. J Biol Chem 287:28163–28168. doi:10.1074/jbc.C112.360800
50. Naj AC et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441. doi:10.1038/ng.801
51. Kiko T et al (2012) Amyloid beta levels in human red blood cells. PloS one 7:e49620. doi:10.1371/journal.pone.0049620
52. Lucas HR, Rifkind JM (2013) Considering the vascular hypothesis of Alzheimer’s disease: effect of copper associated amyloid on red blood cells. Adv Exp Med Biol 765:131–138. doi:10.1007/978-1-4614-4989-8_19
53. Rogers J et al (2006) Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 27:1733–1739
54. Boada M et al (2009) Amyloid-targeted therapeutics in Alzheimer’s disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect 22:325–339. doi:10.1358/dnp.2009.22.6.1395256
55. Sehgal N et al (2012) Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109:3510–3515. doi:10.1073/pnas.1112209109
56. Guan H et al (2008) Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J Neurosci Res. doi:10.1002/jnr.21944
57. Liu Y, Studzinski C, Beckett T, Murphy MP, Klein RL, Hersh LB (2010) Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 45:101–107. doi:10.1016/j.mcn.2010.05.014
58. Henderson SJ et al (2013) Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain. doi:10.1093/brain/awt308
59. Walker JR et al (2013) Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J Neurosci 33:2457–2464. doi:10.1523/JNEUROSCI.3407-12.2013
60. Liu Y et al (2007) In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes. Peptides 28:2348–2355. doi:10.1016/j.peptides.2007.09.015